HROWL
Get informed when a big investor buys or sells
+ Follow| Market cap | $1.43 Billion |
|---|---|
| Enterprise Value | $1.64 Billion |
| Dividend Yield | $1.62 (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.14 |
| Outstanding Shares | 37,231,321 |
| P/E Ratio | -97.96 |
|---|---|
| PEG | -177.33 |
| Price to Sales | 3.66 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.1 |
| Enterprise Value to EBIT | -2145.62 |
| Enterprise Value to Net Income | -110 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 10.47 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...